Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 13/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499648 | 0.88 | RPS6KA5 (0.42) | RPS6KA5FGFR1RPS6KA4METDAO | |
| SCHEMBL29162219 | 0.76 | CA12 (0.43) | DAOCDC7CDK2KDM4EMAPT | |
| SCHEMBL30095634 | 0.74 | CYP11B1 (0.33) | DAOKDM4EMAPT | |
| SCHEMBL29499640 | 0.71 | NQO1 (0.34) | — | |
| SCHEMBL3230718 | 0.68 | BRPF1 (0.50) | RPS6KA5FGFR1RPS6KA4METRAPGEF4 | |
| Hydrochloric Acid SCHEMBL3987570 | 0.67 | BRPF1 (0.48) | RPS6KA5FGFR1RPS6KA4METRAPGEF4 | |
| SCHEMBL30910934 | 0.64 | ATAD2 (0.50) | RPS6KA5FGFR1DAORAPGEF4ATAD2 | |
| SCHEMBL256344 | 0.63 | RPS6KA5 (0.41) | RPS6KA5RPS6KA4METKDM4EMAPT | |
| SCHEMBL29557414 | 0.63 | RPS6KA5 (0.41) | RPS6KA5RPS6KA4METKDM4EMAPT | |
| SCHEMBL17440399 | 0.63 | DAO (0.56) | RPS6KA5FGFR1DAOATAD2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | claimed |
| CN-114302884-A | Substituted pyridopyrimidinone based compounds useful as T cell activators | 百时美施贵宝公司 | 2022-04-08 | — | — | CN | claimed |
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-4301755-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | Juno Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| WO-2022187406-A1 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-114302884-A | Substituted pyridopyrimidinone based compounds useful as T cell activators | 百时美施贵宝公司 | 2022-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | RPS6KA5 192/4885FGFR1 1338/4885RPS6KA4 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.